Axogen, Inc. (AXGN) — SEC Filings
Axogen, Inc. (AXGN) — 35 SEC filings. Latest: 8-K (Apr 28, 2026). Includes 15 8-K, 6 10-Q, 5 SC 13G/A.
View Axogen, Inc. on SEC EDGAR
Overview
Axogen, Inc. (AXGN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 28, 2026: Axogen, Inc. filed an 8-K on April 28, 2026, reporting its financial results for the first quarter of 2026. The filing includes a press release and a financial results presentation detailing the company's performance during the period.
Sentiment Summary
Across 35 filings, the sentiment breakdown is: 3 bullish, 31 neutral, 1 mixed. The dominant filing sentiment for Axogen, Inc. is neutral.
Filing Type Overview
Axogen, Inc. (AXGN) has filed 15 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 5 SC 13G/A, 3 SC 13G, 2 8-K/A with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (35)
Risk Profile
Risk Assessment: Of AXGN's 26 recent filings, 0 were flagged as high-risk, 10 as medium-risk, and 16 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $165.304M |
| Net Income | ($2.547M) |
| EPS | $0.02 |
| Debt-to-Equity | 0.40 |
| Cash Position | $23.902M |
| Operating Margin | 1.16% |
| Total Assets | $216.400M |
| Total Debt | $48.162M |
Key Executives
- PEO1Member
- PEO2Member
- Dr. Steven J. Williams
- Dr. Steven J. Shapiro
- Ms. Karen L. King
- Mr. David M. D. Smith
- Dr. Steven J. Hanley
Industry Context
Axogen operates in the regenerative medicine and biologics sector, focusing on nerve repair solutions. The industry is characterized by high R&D investment, long product development cycles, and significant regulatory oversight. Key trends include advancements in biomaterials and a growing demand for less invasive surgical procedures.
Top Tags
corporate-governance (5) · 8-K (4) · 10-Q (4) · amendment (4) · institutional-ownership (4) · regulation-fd (3) · financial-reporting (3) · disclosure (3) · financials (3) · medical-devices (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Revenue for Q3 2025 | $60.082M | Increased 23.5% from $48.644M in Q3 2024 |
| Revenue for nine months ended Sept 30, 2025 | $165.304M | Increased 19.8% from $137.933M in 2024 |
| Net income for Q3 2025 | $0.708M | Swung from a net loss of $1.858M in Q3 2024 |
| Net loss for nine months ended Sept 30, 2025 | ($2.547M) | Reduced from a net loss of $10.414M in 2024 |
| Cash and cash equivalents as of Sept 30, 2025 | $23.902M | Decreased from $27.554M at Dec 31, 2024 |
| Accumulated deficit as of Sept 30, 2025 | $293.807M | Indicates historical losses despite recent quarterly profit |
| Shares of common stock outstanding | 46,122,289 | As of October 27, 2025 |
| Basic EPS for Q3 2025 | $0.02 | Improved from ($0.04) in Q3 2024 |
| Stock-based compensation for nine months ended Sept 30, 2025 | $13.501M | Increased from $12.830M in 2024 |
| Sales and marketing expenses for nine months ended Sept 30, 2025 | $70.529M | Increased from $58.437M in 2024 |
| Q2 2025 Revenue | $42.5M | increased 18% from Q2 2024 |
| Six-Month 2025 Revenue | $81.2M | increased 16% from six-month 2024 |
| Q2 2025 Net Loss | $8.3M | widened from $7.1M in Q2 2024 |
| Six-Month 2025 Net Loss | $16.5M | widened from $14.0M in six-month 2024 |
| Q2 2025 R&D Expenses | $7.5M | increased from $6.2M in Q2 2024 |
Forward-Looking Statements
- {"claim":"Vanguard will maintain or slightly increase its stake in Axogen over the next year.","entity":"The Vanguard Group","targetDate":"2025-02-13","confidence":"medium"}
- {"claim":"Morgan Stanley will maintain a passive investment in Axogen, Inc. for the foreseeable future.","entity":"Morgan Stanley","targetDate":"December 31, 2024","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Axogen, Inc. (AXGN)?
Axogen, Inc. has 35 recent SEC filings from Jan 2024 to Apr 2026, including 15 8-K, 6 10-Q, 5 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of AXGN filings?
Across 35 filings, the sentiment breakdown is: 3 bullish, 31 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Axogen, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Axogen, Inc. (AXGN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Axogen, Inc.?
Key financial highlights from Axogen, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for AXGN?
The investment thesis for AXGN includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Axogen, Inc.?
Key executives identified across Axogen, Inc.'s filings include PEO1Member, PEO2Member, Dr. Steven J. Williams, Dr. Steven J. Shapiro, Ms. Karen L. King and 2 others.
What are the main risk factors for Axogen, Inc. stock?
Of AXGN's 26 assessed filings, 0 were flagged high-risk, 10 medium-risk, and 16 low-risk.
What are recent predictions and forward guidance from Axogen, Inc.?
Recent forward-looking statements from Axogen, Inc. include guidance on {"claim":"Vanguard will maintain or slightly increase its stake in Axogen over the next year.","entity":"The Vanguard Gr and 1 other predictions.